Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (3,046,894)	$ (7,408,269)
Adjustments to reconcile net loss to net cash from operating activities:
Net unrealized (gain) loss on equity securities at fair value	(1,104,493)	2,553
Net unrealized gain on securities sold, not yet purchased, at fair value	(4,228)	0
Net loss from equity method investments at fair value	27,086	140,694
Net realized (gain) loss on investments	703,907	(151,370)
Impairment loss	0	4,406,249
Straight-line rent	(33,814)	0
Depreciation and amortization	2,197,528	2,280,756
Amortization of deferred financing costs and debt mark-to-market	217,590	301,588
Accretion of above (below) market lease, net	(22,486)	(67,324)
Stock-based compensation	(37,363)	0
Changes in assets and liabilities:
Investments income, rents and other receivables	125,530	(319,497)
Prepaid expenses and other assets	11,261	101,663
Deferred rent and other liabilities	(227,593)	58,063
Accounts payable and accrued liabilities	(815,382)	1,313,789
Due to related entities	(10,203)	(14,536)
Net cash from operating activities	(2,019,554)	644,359
Cash flows from investing activities:
Proceeds from sale of investments	699,622	670,727
Proceeds from securities sold, not yet purchased	305,348	0
Investments in real estate assets	(4,717,178)	(5,826,304)
Purchase of investments	(503,225)	(171,064)
Net cash from investing activities	(4,215,433)	(5,326,641)
Cash flows from financing activities:
Borrowing under mortgage notes payable	6,707,599	5,889,891
Payments on mortgage notes payable	(368,188)	(403,206)
Borrowing under line of credit	412,000	0
Proceeds from notes payable	629,514	0
Payments on notes payable	(6,742)	(4,860)
Payment of financing fees	(137,593)	0
Dividends to common stockholders	0	(1,662,824)
Proceeds from issuance of common stock	172,455	0
Payment on finance lease liabilities	(66,420)	(56,021)	$ (234,109)
Payment of selling commissions and fees	(120,902)	(169,793)
Contributions by non-controlling interests holders	0	359,999
Distributions to non-controlling interests holders	(382,173)	(342,071)
Redemptions of common stock	(1,785)	0
Capital pending acceptance	(10,711)	(200,300)
Net cash from financing activities	7,399,858	3,572,898
Net increase (decrease) in cash, cash equivalents and restricted cash	1,164,871	(1,109,384)
Cash, cash equivalents and restricted cash at beginning of the period	4,116,321	13,077,339	13,077,339
Cash, cash equivalents and restricted cash at end of the period	5,281,192	11,967,955	4,116,321
Cash and cash equivalents at end of the period	4,853,998	10,693,380	3,788,082
Restricted cash at end of the period	427,194	1,274,575	328,239
Total cash, cash equivalents and restricted cash	5,281,192	11,967,955	$ 4,116,321
Supplemental disclosure of non-cash financing activities and other cash flow information:
Cash paid for interest	1,599,640	1,611,521
Capitalized construction in progress outstanding as accounts payable and accrued expenses	1,977,338	670,977
Stock-based compensation	0	465,500
Operating Partnership Class A conversion to common stock	0	859
Main Street West, LP [Member]
Supplemental disclosure of non-cash financing activities and other cash flow information:
Issuance of the Operating Partnership Preferred units for the purchase of Main Street West, LP (Note 1)	0	2,712,194
Green Valley Medical Center, LP [Member]
Supplemental disclosure of non-cash financing activities and other cash flow information:
Fair value of assets acquired from consolidation of Green Valley Medical Center, LP	0	13,621,753
Fair value of liabilities assumed from consolidation of Green Valley Medical Center, LP	0	8,904,457
Series A Preferred Stock [Member]
Cash flows from financing activities:
Dividends to preferred stockholders	(233,759)	(238,403)
Proceeds from issuance of preferred stock	31,000	50,000
Redemptions of Series A preferred stock	(11)	0
Supplemental disclosure of non-cash financing activities and other cash flow information:
Issuance of preferred stock through reinvestment of dividends	53,558	46,333
Issuance Operating Partnership Preferred Units - Series A through reinvestment of dividends	25,995	23,514
Series B Preferred Stock [Member]
Cash flows from financing activities:
Dividends to preferred stockholders	(14,937)	(6,013)
Proceeds from issuance of preferred stock	102,511	356,499
Supplemental disclosure of non-cash financing activities and other cash flow information:
Issuance of preferred stock through reinvestment of dividends	6,328	1,912
Increase in liquidation preference	66,658	34,037
Increase in liquidation preference of Operating Partnership Preferred Units - Series B	24,308	24,307
Series C Common Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of common stock warrants	$ 688,000	$ 0